

Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

<https://marketpublishers.com/r/CFDE3565300BEN.html>

Date: July 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: CFDE3565300BEN

Abstracts

The Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).

This report delivers a comprehensive overview of the Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and

outlook (2024-2031) Scope:

Major Highlights

This report delivers a comprehensive overview of the Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement

and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

COLORECTAL CANCER (CRC)

- The report covers company profiles key players in developing colorectal cancer drug molecules. The company profile includes essential info on overview, financial highlights, product portfolio, business strategies, and key recent developments.

MARKET OUTLOOK

- Colorectal cancer (CRC) is referred to as malignancies that will originate in the rectum or colon also known as bowel cancer.
- The most common feature of colorectal cancer is the formation of adenocarcinomas. The tumor is going to start as a polyp in the inner wall of the colon or rectum, and these polyps may be benign or malignant.
- The risk factors that are involved in causing colorectal cancer include lifestyle changes, genetic disorders, old age, family history, and inflammatory bowel disease.
- Colorectal cancer is symptomized by blood in stool, constipation, a decrease in appetite, weight loss, bloating, nausea, and pelvic pain. Colorectal cancer is categorized into four broad stages. Colorectal cancer is treated by using surgical, radiation, chemotherapeutic, biologic, and immunotherapies.
- Most of the cases of CRC are presented as adenocarcinomas tumors, but other types of CRC involve gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, gastrointestinal stromal tumors, leiomyosarcoma, squamous cell carcinoma, and melanoma.
- The investigational pipeline candidates that are currently under the treatment therapies include promising immunotherapies and chemotherapy drug candidates as well as new combination therapies and targeted therapy drug candidates.

WHAT'S TRENDING IN THIS MARKET?

- These drug candidates fall across all stages of clinical development, among which the majority are being in preclinical and phase I. It shows that 68% of the colorectal cancer drug candidates (CRC) are in preclinical and phase I, among which 45% are in preclinical, and 23% are in phase I stage of development.
- Further investigation shows that more CRC drug candidates currently are found in discovery, an investigational new drug (IND)/clinical trial application (CTA) filed phases compared to that in phase III.
- It shows that there are many more upcoming opportunities, which will increase the development of colorectal cancer products through all the clinical stages.
- Further, this moderate growth will be hindered by the uptake of lower-priced biosimilar versions of cetuximab and bevacizumab due to the expiration of the patent of Avastin and Erbitux. It is also expected that the introduction of generic versions of capecitabine will also affect market growth.

- However, this can be balanced by the introducing premium-priced emerging therapies. One of the biggest drivers of growth in the CRC market is expected to be Stivarga drug treatment, firstly due to the scheduled line extension as a maintenance treatment drug for patients with resected liver metastases in the first-line metastatic setting.
- The launch of Lonsurf (TAS-102) found in the third and fourth-line settings is going to further increase the rates of pharmacological treatment in these lines that will provide the patients a more tolerable alternative to Stivarga treatment.
- The moderate expected uptake of other late-stage pipeline products like panitumumab and Xilonix, following the expected approval, is going to drive additional growth within the market.

DRIVERS & RESTRAINTS

- The primary drivers of growth include the expected increased number of diagnosed CRC incidence cases and the launch and uptake of the premium-priced therapies for treatment.
- Traditionally, two therapeutic classes have dominated the CRC market including Angiogenesis and EGFR inhibitors. The prediction that the branded drugs used to facilitate the gradual increase in the number of patients.
- With branded therapy across different lines of metastatic treatment, an increase in the patient pool of these segments and also the overall CRC market size shall be noticed.
- Loss of patent exclusivity of many developers is going to challenge for introducing new candidates that will increase the growth of the market. The dominated natures of biologics among other therapeutics are the trending currently in the market.

THE SCOPE OF THE REPORT

- Provides comprehensive understanding of active colorectal cancer pipeline drug candidates
- Includes comprehensive pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.
- Offers pipeline assessment by monotherapy, combination therapy products, and route of administration
- Provides a comparative analysis of key marketed products and pipeline drug candidates
- Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators
- Provides essential info on players involved in clinical R&D of colorectal cancer drug candidates.
- Provides in-depth coverage of significant news related to colorectal cancer drug molecules, including significant mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.

WHY SHOULD I PURCHASE THIS REPORT?

- To obtain an understanding of the current colorectal cancer pipeline landscape.
- To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.
- To valuably optimize R&D activities in-line with robust therapeutic drug markets.
- To devise strategic initiatives by identifying prospective partners with progressing projects.

I would like to order

Product name: Colorectal Cancer (CRC) – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

Product link: <https://marketpublishers.com/r/CFDE3565300BEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CFDE3565300BEN.html>